Lei Qin

Lei Qin

AstraZeneca, Sweden - Södertälje / Sweden
Economics & Econometrics / Economics
AD Scientific Index ID: 4532913
-
person_outline Lei Qin's MOST POPULAR ARTICLES
1-) Cost‐effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health‐economic analysis of DAPA‐HFP McEwan, O Darlington, JJV McMurray, PS Jhund, KF Docherty, M Böhm, ...European journal of heart failure 22 (11), 2147-2156, 2020702020
2-) Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21 334 patients in the UKC Linde, L Qin, A Bakhai, H Furuland, M Evans, D Ayoubkhani, E Palaka, ...ESC heart failure 6 (2), 280-290, 2019572019
3-) Real‐world associations of renin–angiotensin–aldosterone system inhibitor dose, hyperkalemia, and adverse clinical outcomes in a cohort of patients with new‐onset chronic …C Linde, A Bakhai, H Furuland, M Evans, P McEwan, D Ayoubkhani, L QinJournal of the American Heart Association 8 (22), e012655, 2019442019
4-) Serum potassium as a predictor of adverse clinical outcomes in patients with chronic kidney disease: new risk equations using the UK clinical practice research datalinkH Furuland, P McEwan, M Evans, C Linde, D Ayoubkhani, A Bakhai, ...BMC nephrology 19, 1-16, 2018562018
5-) Glucagon-like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Naïve Patients with Type 2 Diabetes Mellitus: A Multinational Preference StudyL Qin, S Chen, E Flood, A Shaunik, B Romero, M Cruz, C Alvarez, ...Diabetes Therapy, 1-14, 201754*2017